Gerresheimer has launched Gx InMonit, a novel smart add‑on device designed to enhance patient support and engagement for autoinjector‑based home treatments.
The new solution, introduced alongside the AI‑enabled Gx AdheraLink messaging platform, aims to improve adherence, provide objective compliance data and strengthen treatment outcomes for pharmaceutical companies and patients alike.
Mounted directly onto an autoinjector, such as those in Gerresheimer’s Gx Inbeneo range, Gx InMonit guides patients through the full injection process.
It features a clear, high‑contrast AMOLED screen and audible prompts that convey step‑by‑step instructions, from preparation and initiation to completion of the injection.
Motion sensors detect key events — including start, premature removal or potential injection failure — helping to ensure correct administration in line with prescribed regimens.
In addition to its interactive guidance, Gx InMonit captures detailed real‑time data at the point of administration.
This information, including timing, temperature and device verification via integrated NFC scanning, is transmitted automatically to the cloud using cellular networks.
The automated data capture requires no manual pairing, app installation or uploads, simplifying use for patients and caregivers.
Complementing the hardware, Gx AdheraLink delivers personalised, AI‑powered messaging to patients before and after injections through widely used instant messaging platforms such as WhatsApp or iMessage.
The solution does not require new app downloads or additional accounts, reducing barriers for patients.
Preinjection reminders aim to prepare and motivate patients, while post‑injection messages reinforce positive engagement and invite patient feedback on their experience, such as injection location, perceived pain levels and overall satisfaction.
Crucially, the combined system creates a unified ecosystem that delivers richer insights into patient behaviour and adherence trends.
Pharmaceutical companies can access anonymised real‑world data on use patterns, enabling them to evaluate and optimise support strategies.
Feedback loops built into the platform allow effective engagement techniques to be identified and strengthened with time.
Gerresheimer says this innovation supports its broader commitment to advancing digital health solutions that improve adherence and therapy effectiveness, while providing robust data that can inform drug development, regulatory compliance and patient outcomes.
